BR112014020212A8 - aminopirazina, formulação farmacêutica, processo para a preparação de um derivado de aminopirazina, e, intermediário. - Google Patents
aminopirazina, formulação farmacêutica, processo para a preparação de um derivado de aminopirazina, e, intermediário.Info
- Publication number
- BR112014020212A8 BR112014020212A8 BR112014020212A BR112014020212A BR112014020212A8 BR 112014020212 A8 BR112014020212 A8 BR 112014020212A8 BR 112014020212 A BR112014020212 A BR 112014020212A BR 112014020212 A BR112014020212 A BR 112014020212A BR 112014020212 A8 BR112014020212 A8 BR 112014020212A8
- Authority
- BR
- Brazil
- Prior art keywords
- aminopyrazine
- pharmaceutical formulation
- preparing
- derivative
- present
- Prior art date
Links
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000004792 malaria Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261600324P | 2012-02-17 | 2012-02-17 | |
| US61/600,324 | 2012-02-17 | ||
| PCT/IB2013/051235 WO2013121387A1 (en) | 2012-02-17 | 2013-02-15 | Anti -malarial agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112014020212A8 true BR112014020212A8 (pt) | 2018-01-23 |
| BR112014020212B1 BR112014020212B1 (pt) | 2021-11-23 |
Family
ID=48014134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014020212-5A BR112014020212B1 (pt) | 2012-02-17 | 2013-02-15 | Aminopirazina, formulação farmacêutica, método para prevenir ou tratar malária em um paciente, processo para a preparação de um derivado de aminopirazina, e, intermediário |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9266842B2 (pt) |
| EP (1) | EP2814820B1 (pt) |
| JP (1) | JP6226889B2 (pt) |
| CN (1) | CN104136426B (pt) |
| BR (1) | BR112014020212B1 (pt) |
| CA (1) | CA2864483A1 (pt) |
| CY (1) | CY1118074T1 (pt) |
| DK (1) | DK2814820T3 (pt) |
| ES (1) | ES2589283T3 (pt) |
| HK (1) | HK1202859A1 (pt) |
| HR (1) | HRP20161237T1 (pt) |
| HU (1) | HUE029876T2 (pt) |
| IN (1) | IN2014MN01622A (pt) |
| LT (1) | LT2814820T (pt) |
| ME (1) | ME02535B (pt) |
| PL (1) | PL2814820T3 (pt) |
| PT (1) | PT2814820T (pt) |
| SI (1) | SI2814820T1 (pt) |
| SM (1) | SMT201600441B (pt) |
| WO (1) | WO2013121387A1 (pt) |
| ZA (1) | ZA201406786B (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2589283T3 (es) * | 2012-02-17 | 2016-11-11 | University Of Cape Town | Agentes anti-malaria |
| EP3118198A1 (en) | 2015-07-13 | 2017-01-18 | MMV Medicines for Malaria Venture | Anti-malarial agents |
| WO2017067881A1 (en) | 2015-10-19 | 2017-04-27 | Glaxosmithkline Intellectual Property Development Limited | Pyrazine compounds for use in the treatment of parasitic protozoal infections |
| US11453657B2 (en) * | 2018-01-24 | 2022-09-27 | Glaxosmithkline Intellectual Property Development Limited | Compounds for the treatment of parasitic infections |
| CN112142715A (zh) * | 2020-10-10 | 2020-12-29 | 鲁南制药集团股份有限公司 | 一种2-氨基-5-杂环基取代的吡嗪衍生物及其用途 |
| AU2022395361A1 (en) * | 2021-11-23 | 2024-05-30 | Glaxosmithkline Intellectual Property Development Limited | Pyrazine compounds useful in the treatment of parasitic protozoal infection |
| WO2024033280A1 (en) | 2022-08-09 | 2024-02-15 | Merck Patent Gmbh | Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria |
| WO2024033281A1 (en) | 2022-08-09 | 2024-02-15 | Merck Patent Gmbh | Furo pyrimidine derivates |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004294354B2 (en) * | 2003-12-03 | 2009-02-19 | Ym Biosciences Australia Pty Ltd | Tubulin inhibitors |
| CN101472912A (zh) * | 2006-06-22 | 2009-07-01 | 比奥维特罗姆上市公司 | 作为mnk激酶抑制剂的吡啶和吡嗪衍生物 |
| EP1900727A1 (en) * | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| GB0625659D0 (en) * | 2006-12-21 | 2007-01-31 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| SI2526090T1 (sl) | 2010-01-18 | 2015-11-30 | Mmv Medicines For Malaria Venture | Nova sredstva proti malariji |
| EP2569286B1 (en) * | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| KR20140014205A (ko) * | 2011-03-04 | 2014-02-05 | 렉시컨 파마슈티컬스 인코퍼레이티드 | Mst1 키나제 억제제 및 그의 사용 방법 |
| ES2589283T3 (es) * | 2012-02-17 | 2016-11-11 | University Of Cape Town | Agentes anti-malaria |
-
2013
- 2013-02-15 ES ES13712926.8T patent/ES2589283T3/es active Active
- 2013-02-15 US US14/379,332 patent/US9266842B2/en not_active Expired - Fee Related
- 2013-02-15 LT LTEP13712926.8T patent/LT2814820T/lt unknown
- 2013-02-15 JP JP2014557157A patent/JP6226889B2/ja not_active Expired - Fee Related
- 2013-02-15 CA CA2864483A patent/CA2864483A1/en not_active Abandoned
- 2013-02-15 SI SI201330290A patent/SI2814820T1/sl unknown
- 2013-02-15 ME MEP-2016-214A patent/ME02535B/me unknown
- 2013-02-15 CN CN201380009373.9A patent/CN104136426B/zh not_active Expired - Fee Related
- 2013-02-15 DK DK13712926.8T patent/DK2814820T3/en active
- 2013-02-15 PT PT137129268T patent/PT2814820T/pt unknown
- 2013-02-15 WO PCT/IB2013/051235 patent/WO2013121387A1/en active Application Filing
- 2013-02-15 BR BR112014020212-5A patent/BR112014020212B1/pt not_active IP Right Cessation
- 2013-02-15 EP EP13712926.8A patent/EP2814820B1/en active Active
- 2013-02-15 PL PL13712926T patent/PL2814820T3/pl unknown
- 2013-02-15 IN IN1622MUN2014 patent/IN2014MN01622A/en unknown
- 2013-02-15 HU HUE13712926A patent/HUE029876T2/en unknown
-
2014
- 2014-09-16 ZA ZA2014/06786A patent/ZA201406786B/en unknown
-
2015
- 2015-04-01 HK HK15103337.9A patent/HK1202859A1/xx not_active IP Right Cessation
-
2016
- 2016-09-28 HR HRP20161237TT patent/HRP20161237T1/hr unknown
- 2016-10-10 CY CY20161100998T patent/CY1118074T1/el unknown
- 2016-12-02 SM SM201600441T patent/SMT201600441B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2814820B1 (en) | 2016-07-20 |
| PT2814820T (pt) | 2016-10-25 |
| SI2814820T1 (sl) | 2016-10-28 |
| LT2814820T (lt) | 2016-10-25 |
| US9266842B2 (en) | 2016-02-23 |
| ZA201406786B (en) | 2015-06-24 |
| CA2864483A1 (en) | 2013-08-22 |
| DK2814820T3 (en) | 2016-10-03 |
| CY1118074T1 (el) | 2017-06-28 |
| PL2814820T3 (pl) | 2017-01-31 |
| JP2015507004A (ja) | 2015-03-05 |
| CN104136426B (zh) | 2017-10-03 |
| EP2814820A1 (en) | 2014-12-24 |
| WO2013121387A1 (en) | 2013-08-22 |
| IN2014MN01622A (pt) | 2015-05-15 |
| US20150031682A1 (en) | 2015-01-29 |
| JP6226889B2 (ja) | 2017-11-08 |
| HK1202859A1 (en) | 2015-10-09 |
| CN104136426A (zh) | 2014-11-05 |
| ME02535B (me) | 2017-02-20 |
| HRP20161237T1 (hr) | 2016-11-04 |
| BR112014020212B1 (pt) | 2021-11-23 |
| SMT201600441B (it) | 2017-01-10 |
| ES2589283T3 (es) | 2016-11-11 |
| HUE029876T2 (en) | 2017-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014020212A8 (pt) | aminopirazina, formulação farmacêutica, processo para a preparação de um derivado de aminopirazina, e, intermediário. | |
| WO2011086531A3 (en) | New anti-malarial agents | |
| CL2014003566A1 (es) | Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson. | |
| EA201600204A1 (ru) | Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли | |
| BR112014003681A2 (pt) | composto, composição farmacêutica, produto de combinação farmacêutica, uso de um composto, e, método para tratar doenças ou condições | |
| CY1120715T1 (el) | Παραγωγα ετεροαρυλιου βουτανικου οξεος ως αναστολεις lta4h | |
| ES2694290T5 (es) | Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por CFTR | |
| ECSP14026138A (es) | Uracilos sustituidos bicíclicamente y uso de los mismos | |
| BR112013013435A2 (pt) | composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma cinase de fgfr, e, processo para a preparação de um composto. | |
| BR112014010206B8 (pt) | composto derivado de piridopirazina, composição farmacêutica, e, uso de um composto | |
| BR112014010183B8 (pt) | Composto, composição farmacêutica, produto, e, uso de um composto | |
| UY34917A (es) | Inhibidores de la producción de leucotrieno-a4-hidrolasa (lta4h), composiciones farmacéuticas que los contienen y proceso para su preparación | |
| BR112014014452A2 (pt) | derivados de pirazolpiridina, processo de preparação dos mesmos e uso terapêutico dos mesmos | |
| WO2013134047A3 (en) | Aminoquinoline derivatives and uses thereof | |
| BR112015002755A2 (pt) | derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico, método de modificação de derivado de ácido hialurônico e uso de derivados | |
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| BR112014013354A2 (pt) | processo para a preparação de um polímero, composição, composto, e, formulação | |
| UY35747A (es) | Derivados sustituidos de fenilalanina | |
| BR112016024421A2 (pt) | composição farmacêutica, cápsula e uso da composição farmacêutica | |
| UY35746A (es) | Derivados de fenilalanina sustituidos | |
| UY35745A (es) | Derivados sustituidos de fenilalanina | |
| BR112017002852A2 (pt) | compostos de azetidiniloxifenilpirrolidina | |
| BR112014018712A8 (pt) | Derivados de morfolinila úteis como inibidores de mogat-2 | |
| BR112016013946A8 (pt) | quinazolin-thf-aminas como inibidores de pde1, composição farmacêutica que os compreende, processo para preparação da referida composição farmacêutica, bem como uso dos composto e kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/02/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2710 DE 13-12-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |